NaturalAntibody S.A. announces a strategic collaboration with Boehringer Ingelheim to develop and apply digital methods for the development of therapeutic monoclonal antibodies (mAbs) with the aim of accelerating the discovery of new biotherapeutics in areas of high unmet patient need.

We show that fine-tuning such a pre-trained network on a task of shape prediction on real X-ray structures improves the number of correct peptide bond distances. We further demonstrate that pre-training allows the network to produce physically plausible shapes on an artificial set of CDR-H3s, showing the ability to generalise to the vast antibody sequence space.

The NaturalAntibody platform now includes a feature called Batch Sequence Annotation. Users can upload a batch of sequences and filter it by specific attributes to quickly find the most promising candidates and accelerate their work.

There is no question that drug discovery has become increasingly competitive and expensive, driving pharmaceutical companies to look into new methods for reducing R&D costs. Artificial Intelligence promises to solve key industry challenges and significantly speed up the discovery process to help companies reclaim a sizeable chunk of their costs.

What can leaders do today to keep that focus and persevere through the economic downturn? I believe the answer lies in AI and its potential for redefining business processes and models.

The bioinformatics company NaturalAntibody released an Antibody Discovery Platform - a web-based solution that helps scientists discover antibody-based drug candidates to speed up research decision-making.

Our review provides a critical overview of the recent developments in deep learning approaches to therapeutic antibody design, with implications for fully computational antibody design.

NaturalAntibody, the leading bioinformatics company accelerating antibody discovery with AI-based products for the pharma industry, has launched a partnership with Icosagen Cell Factory (CRDMO) - experts in discovering and producing antibodies with pharma companies.

Can AlphaFold2 help in the antibody discovery process? Our team at NaturalAntibody carried out some tests to check its potential. Read this article to find out what we discovered.

Antibodies represent the fastest-growing class of biotherapeutics on the market because of their naturally favorable attributes. How can pharmaceutical companies harness the potential of antibodies with the help of computational solutions based on AI?

​​We have great news to share - Dr. Sonia Wróbel joined NaturalAntibody as Senior Product Manager! Dr. Wróbel has over 6 years of experience in the biotechnology industry across a range of business roles. As a holder of both doctoral and MBA degrees, Dr. Wróbel has experience in bringing complex scientific products to market. She is going to support our team in realizing our mission of accelerating antibody-based drug discovery to deliver life-saving therapeutics faster.

What's it like to work in an R&D-led biotechnology startup? What challenges do software development teams solve, and what skills can they acquire? Read this interview with Piotr, our VP of Engineering, to get the scoop on a developer's work in this unique setting.

AbDiver is an online tool that helps researchers make the most of the vast NGS data on antibody mutations by allowing them to spot parallels between natural and therapeutic antibodies. AbDiver accelerates the decision-making process during the lead optimization stage for a more efficient therapeutic pipeline.

An essential prerequisite for antibody analysis is the use of standardized numbering methods. What exactly is antibody numbering and how does it work?

NaturalAntibody, a bioinformatics company developing computational methods for antibody-based drug discovery, has appointed Piotr Deszyński as VP of Engineering, a tech leader with over 15 years of experience in the industry across CTO and tech lead roles.

Where do antibodies come from? What is the structure of an antibody? And how does it all work? Keep on reading to learn the essentials of antibody function and how it comes about as a result of its sequence and structure.

NaturalAntibody, the leading bioinformatics company accelerating antibody discovery with AI-based solutions for the pharma industry, was awarded a $1.7 million grant from the National Centre for Research and Development for industrial Research & Development projects.

Get a (brief) introduction to antibody therapeutics, different techniques for antibody engineering, and context on how computational approaches are now steadily transforming this rapidly expanding field.

To design nanobody-based drugs, scientists need databases that collate the increasing volume of biological sequence data in the public domain. To address this problem, we developed Integrated Nanobody Database for Immunoinformatics (INDI) - a novel nanobody database that collates nanobody information from all the major data repositories in the public domain.

AbDiver is an online platform that helps scientists to navigate the vast NGS data sets on antibody mutations. Allowing to draw parallels between natural and therapeutic antibodies, the solution supports and accelerates the decision-making process in the rational design of therapeutics at the lead optimization stage for a faster therapeutic pipeline.

We’re excited to share that the Management Board of NaturalAntibody was awarded a top 10 position in the 11th edition of the 50 Most Creative People in Business Ranking.

By accessing antibody data in patent documents via NaturalAntibody infrastructure, researchers can accelerate the antibody development process. They can quickly check whether the sequence they’re working on has already been developed by another company and use data stored in patents to study similar antibodies with their targets and engineering properties.

​​We have fantastic news to share today - Jakob Saga joined NaturalAntibody as Chief Commercial Officer! Mr. Saga has over 12 years of experience in the pharmaceutical industry, working as a Finance Manager and CFO in globally renowned companies. His business acumen and expert knowledge are going to support our team in realizing our mission of accelerating antibody-based drug discovery to deliver life-saving therapeutics faster.